Carbohydrate antigen 19-9-positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine.
We performed a radical retropubic prostatectomy on a 59-year-old male patient who was diagnosed with prostatic carcinoma. Pathological findings revealed a ductal adenocarcinoma in the left lobe of the prostate, and a conventional well-differentiated adenocarcinoma in the right lobe. Immunohistochemistry revealed that CA19-9 was positive in the ductal adenocarcinoma, and prostate-specific antigen was positive in the conventional well-differentiated adenocarcinoma. Since there was an increase in the level of serum CA19-9, which had decreased postoperatively, along with the appearance of local recurrence and bone metastasis, we treated the patient with cisplatin and gemcitabine. As a result, the level of serum CA19-9 was normalized and a reduction of the metastatic focus was observed.
Kato
Toshiki
T
Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. toshiki@med.nagoya-cu.ac.jp
Hashimoto
Yoshihiro
Y
Okada
Shinsuke
S
Tozawa
Keiichi
K
Takahashi
Satoru
S
Kohri
Kenjiro
K
D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018395:CA-19-9 Antigen / Q000235:genetics / Q000378:metabolism*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D018395:CA-19-9 Antigen; D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine